Head to Head Comparison: Synlogic (NASDAQ:SYBX) and Hillstream BioPharma (NASDAQ:HILS)

Hillstream BioPharma (NASDAQ:HILS) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Hillstream BioPharma and Synlogic”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream BioPharma	N/A	N/A	-$8.47 million	($0.72)	-3.38
Synlogic	$3.37 million	4.72	-$57.28 million	($4.16)	-0.33

Hillstream BioPharma has higher earnings, but lower revenue than Synlogic. Hillstream BioPharma is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hillstream BioPharma has a beta of 3.08, meaning that its stock price is 208% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

13.4% of Hillstream BioPharma shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 30.2% of Hillstream BioPharma shares are held by insiders. Comparatively, 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Hillstream BioPharma and Synlogic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream BioPharma	0	0	0	0	0.00
Synlogic	0	4	1	0	2.20

Synlogic has a consensus target price of $30.00, suggesting a potential upside of 2,105.88%. Given Synlogic’s stronger consensus rating and higher possible upside, analysts plainly believe Synlogic is more favorable than Hillstream BioPharma.

Profitability

This table compares Hillstream BioPharma and Synlogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream BioPharma	N/A	-188.44%	-149.61%
Synlogic	-2,284.65%	-207.84%	-114.81%

Summary

Synlogic beats Hillstream BioPharma on 7 of the 13 factors compared between the two stocks.

About Hillstream BioPharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.